Giuseppe Minniti

TL;DR: Results of the National Cancer Institute of Canada Clinical Trials Group and European Organization for Research and Treatment of Cancer randomized study of short-course RT with or without concurrent and adjuvant temozolomide have demonstrated a significant improvement in progression-free survival and overall survival for patients receiving RT and temozoomide over RT alone, without impairing either quality of life or functional status.

TL;DR: In this article, the clinical outcome of a large series of patients operated on for a secreting pituitary adenoma according to the most recent stringent criteria of biochemical remission nowadays accepted was reported.

TL;DR: In this paper, the diagnostic information obtained with 6-[18F]-fluoro-l-3,4-dihydroxyphenylalanine (F-DOPA) PET and relative cerebral blood volume (rCBV) maps in recurrent or progressive glioma was compared and their spatial congruence calculated.

TL;DR: In this article, the authors provide a clinical overview on current status and recent advances in re-radiation of GBM, addressing relevant clinical questions such as the appropriate patient selection and radiation technique, optimal dose fractionation, reirradiation tolerance of the brain and the risk of radiation necrosis.

TL;DR: This study confirms the favorable prognostic value of IDH1 mutation and MGMT methylation in patients with AA treated with RT plus concomitant and adjuvant TMZ, and the superiority of combined radiochemotherapy over other treatment modalities remains to be demonstrated.